- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Primary hyperoxaluria type 1
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Lumasiran – March 2025
Lumasiran; Solution for subcutaneous injection 94.5 mg in 0.5 mL; Oxlumo®
Last updated
12 March 2025